Takeda Halts Development Of Diabetes Agent TAK-379
This article was originally published in PharmAsia News
Executive Summary
Takeda announced April 21 it would discontinue clinical development of diabetes agent TAK-379 because it did not meet internal criteria to support further development. An insulin sensitizer, TAK-379 was in Phase II trials in the U.S. and Europe and in Phase I in Japan
You may also be interested in...
Takeda Looks To Counter R&D Setbacks With Ramped Up Sales Efforts
TOKYO - Having suffered considerable setbacks in launching its core pipeline drugs, Takeda Pharmaceutical will focus on expanding sales growth of existing products, including the gastronomic treatment Kapidex (dexlansoprazole) and gout medication Uloric (febuxostat) that were approved by U.S. FDA in early 2009, the company said in its earnings report and related documents May 11
Takeda Looks To Counter R&D Setbacks With Ramped Up Sales Efforts
TOKYO - Having suffered considerable setbacks in launching its core pipeline drugs, Takeda Pharmaceutical will focus on expanding sales growth of existing products, including the gastronomic treatment Kapidex (dexlansoprazole) and gout medication Uloric (febuxostat) that were approved by U.S. FDA in early 2009, the company said in its earnings report and related documents May 11
Takeda Takes Back Actos Rights from Eli Lilly, Sets Course For Own Geographic Expansion
Takeda is taking back marketing rights to type 2 diabetes treatment Actos (pioglitazone) from Eli Lilly in Canada and six other countries as early as this year, according to the two companies